North America DNA Sequencing Market to Reach $27.56 Billion by 2035, Driven by Precision Medicine and Oncology Applications
核心洞察
The North America DNA sequencing market was valued at USD 7.5 billion in 2025 and is projected to reach USD 27.56 billion by 2035, growing at a CAGR of 13.9%.
Next-generation sequencing dominates the technology segment with a 63.80% share in 2025, while consumables lead product categories at 54.70%.
Oncology represents the largest application segment at 29.40%, reflecting high cancer (搜索) prevalence and the shift toward targeted tumor profiling and companion diagnostics.
The North America DNA sequencing market, valued at USD 7.5 billion in 2025, is forecast to reach approximately USD 27.56 billion by 2035, expanding at a compound annual growth rate (CAGR) of 13.9% from 2026 to 2035, according to market research from Precedence Research. The region maintains the largest global market share, underpinned by a strong biotechnology infrastructure, leadership in precision medicine, and a high concentration of research institutions, clinical laboratories, and biopharmaceutical companies.
The market's expansion is fueled by growing adoption of precision medicine, significant federal and private-sector investments in genomics research, and rising incidence of cancer (搜索) and rare genetic diseases (搜索). The National Institutes of Health (NIH) and other funding bodies continue to support large-scale genomic initiatives that drive demand for sequencing instruments, consumables, and services.
Technology Landscape: NGS Maintains Dominance
Next-generation sequencing (NGS) commanded a 63.80% share of the North America DNA sequencing market in 2025, reflecting its high throughput, rapid turnaround times, and essential role in precision medicine. NGS platforms enable advanced oncology profiling, rare disease detection, and cost-effective clinical diagnostics at scale.
Third-generation DNA sequencing (TGS) accounted for 22.40% of the market in 2025, gaining traction due to its long-read capabilities that allow real-time tracking of single molecules. TGS technologies are particularly valuable for resolving complex structural genomic variants and advancing oncology research. Sanger sequencing comprises the remaining share, serving niche applications requiring targeted, high-accuracy reads.
Product Segments: Consumables Drive Recurring Revenue
Consumables led all product categories with a 54.70% market share in 2025, generating ongoing revenue through necessary daily-use reagents, kits, and supplies that support high-throughput clinical and research workflows. Instruments represented 25.80% of the market, supplying essential hardware for NGS and facilitating rapid clinical diagnostics. The services segment, at 19.50%, demonstrated the fastest growth trajectory by offering essential bioinformatics capabilities that minimize the need for expensive in-house equipment and support precision medicine initiatives.
Oncology Dominates Applications
Oncology emerged as the leading application segment with a 29.40% share in 2025, driven by high cancer (搜索) prevalence, a significant shift toward precision medicine, and substantial genomics investments. The segment derives the largest revenue share through targeted tumor profiling and companion diagnostics. Clinical investigation followed at 26.10%, transforming genomic sequencing from fundamental research into routine patient care through personalized medicine approaches and robust insurance reimbursement systems.
Additional application areas include reproductive health, forensics and agrigenomics, HLA typing, and other emerging clinical and research uses.
End-Use: Clinical Research Leads Adoption
Clinical research represented the largest end-use segment at 28.70% in 2025, promoting precision medicine, accelerating targeted oncology treatments, and improving clinical trial designs. Academic research accounted for 21.90%, fostering foundational genomic innovation and attracting substantial government and institutional funding. Both segments benefit from the region's advanced healthcare systems and strong institutional support.
Competitive Landscape
The North American DNA sequencing market is concentrated around a few key hardware and consumable suppliers. Illumina, Inc. holds the largest market share with its sequencing-by-synthesis systems, offering products ranging from ultra-high-throughput NovaSeq platforms to benchtop MiSeq and NextSeq models, alongside clinical assay kits.
Thermo Fisher Scientific (搜索) maintains a strong position in clinical and targeted sequencing through its Ion Torrent systems, including the Ion GeneStudio S5, and RapidHIT platforms for quick human identification and targeted oncology applications. Pacific Biosciences (搜索) (PacBio) focuses on high-accuracy long-read sequencing with Sequel and Revio systems utilizing HiFi sequencing chemistry for analyzing complex structural variants.
Oxford Nanopore Technologies (搜索) offers scalable, real-time nanopore-based sequencing spanning portable MinION devices to high-throughput PromethION benchtop stations. Element Biosciences (搜索) has emerged as a disruptive player with its AVITI system, targeting reduced per-gigabase running costs for standard genomic workflows. Agilent Technologies (搜索) provides specialized target enrichment solutions, including SureSelect panels and quality analysis tools, while QIAGEN leads in sample preparation with QIAseq library preparation kits, automated extraction instruments, and specialized bioinformatics pipelines.
Broader Context: Whole Genome Sequencing Growth
Complementary market data from Business Research Insights indicates the global whole genome sequencing market is projected to reach USD 53.21 billion by 2035, growing at a CAGR of 34.51% from 2026. More than 8 million human genomes had been sequenced globally by 2025, compared with fewer than 1 million a decade earlier. Sequencing accuracy now exceeds 99.9% on leading platforms, and over 70 countries have established national genomics programs supporting large-scale genome analysis.
The United States remains the largest contributor, with more than 1.3 million genomes analyzed through government-supported precision medicine programs by 2025. Over 3,500 certified molecular laboratories provide advanced genomic testing services, and cancer (搜索)-related genomic studies account for nearly 40% of sequencing activities across major research institutions.